Development of a label-free LC-MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical trial of combined hormone and radiation therapy.

Hdl Handle:
http://hdl.handle.net/10147/324245
Title:
Development of a label-free LC-MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical trial of combined hormone and radiation therapy.
Authors:
Morrissey, Brian; O'Shea, Carmel; Armstrong, John; Rooney, Cathy; Staunton, Lisa; Sheehan, Martina; Shannon, Aoife M; Pennington, Stephen R
Affiliation:
Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin, Ireland.
Citation:
Morrissey B et al. Development of a label-free LC-MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical trial of combined hormone and radiation therapy. Proteomics Clin Appl. 2013, 7 (5-6):316-26
Journal:
Proteomics. Clinical applications
Issue Date:
Jun-2013
URI:
http://hdl.handle.net/10147/324245
DOI:
10.1002/prca.201300004
PubMed ID:
23670859
Abstract:
Combined hormone and radiation therapy (CHRT) is one of the principle curative regimes for localised prostate cancer (PCa). Following treatment, many patients subsequently experience disease recurrence however; current diagnostics tests fail to predict the onset of disease recurrence. Biomarkers that address this issue would be of significant advantage.
Item Type:
Article
Language:
en
Keywords:
PROSTATE CANCER
Local subject classification:
RADIATION THERAPY; HORMONE THERAPY
MeSH:
Antineoplastic Agents, Hormonal; Blood Proteins; Chromatography, High Pressure Liquid; Combined Modality Therapy; Humans; Male; Nanotechnology; Principal Component Analysis; Prostatic Neoplasms; Recurrence; Tandem Mass Spectrometry; Time Factors; Trypsin; Tumor Markers, Biological
ISSN:
1862-8354

Full metadata record

DC FieldValue Language
dc.contributor.authorMorrissey, Brianen_GB
dc.contributor.authorO'Shea, Carmelen_GB
dc.contributor.authorArmstrong, Johnen_GB
dc.contributor.authorRooney, Cathyen_GB
dc.contributor.authorStaunton, Lisaen_GB
dc.contributor.authorSheehan, Martinaen_GB
dc.contributor.authorShannon, Aoife Men_GB
dc.contributor.authorPennington, Stephen Ren_GB
dc.date.accessioned2014-08-05T12:03:46Z-
dc.date.available2014-08-05T12:03:46Z-
dc.date.issued2013-06-
dc.identifier.citationMorrissey B et al. Development of a label-free LC-MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical trial of combined hormone and radiation therapy. Proteomics Clin Appl. 2013, 7 (5-6):316-26en_GB
dc.identifier.issn1862-8354-
dc.identifier.pmid23670859-
dc.identifier.doi10.1002/prca.201300004-
dc.identifier.urihttp://hdl.handle.net/10147/324245-
dc.description.abstractCombined hormone and radiation therapy (CHRT) is one of the principle curative regimes for localised prostate cancer (PCa). Following treatment, many patients subsequently experience disease recurrence however; current diagnostics tests fail to predict the onset of disease recurrence. Biomarkers that address this issue would be of significant advantage.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Proteomics. Clinical applicationsen_GB
dc.subjectPROSTATE CANCERen_GB
dc.subject.meshAntineoplastic Agents, Hormonal-
dc.subject.meshBlood Proteins-
dc.subject.meshChromatography, High Pressure Liquid-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshNanotechnology-
dc.subject.meshPrincipal Component Analysis-
dc.subject.meshProstatic Neoplasms-
dc.subject.meshRecurrence-
dc.subject.meshTandem Mass Spectrometry-
dc.subject.meshTime Factors-
dc.subject.meshTrypsin-
dc.subject.meshTumor Markers, Biological-
dc.subject.otherRADIATION THERAPYen_GB
dc.subject.otherHORMONE THERAPYen_GB
dc.titleDevelopment of a label-free LC-MS/MS strategy to approach the identification of candidate protein biomarkers of disease recurrence in prostate cancer patients in a clinical trial of combined hormone and radiation therapy.en_GB
dc.typeArticleen
dc.contributor.departmentConway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin, Ireland.en_GB
dc.identifier.journalProteomics. Clinical applicationsen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.